News – Page 1177 – Endpoints News

Allergan’s executive team orchestrates a $200M buyout to beef up gastroenterology pipeline

9 years ago

Turning pharma castoffs into an instant fortune, Vivek Ramaswamy’s Myovant bags a $218M IPO

9 years ago

Humana spells out its conditional Exondys 51 coverage policy — strings attached

9 years ago

Auven Therapeutics sells PhIII dry eye disease drug to Sun for $40M-plus

9 years ago

GV backs new genomics R&D upstart; Vertex advances plans for next-gen CF drugs

9 years ago

GlaxoSmithKline sounds taps for a once-mighty R&D program

9 years ago

Boehringer flags PhIII success for another Humira knockoff, setting up a crowded field of cheaper rivals — ...

9 years ago

Biogen quietly whisks away its $544M autoimmune rival to Celgene

9 years ago

Merck and Novartis chiefs outline what's on the M&A menu in 2017

9 years ago

AstraZeneca celebrates a PhIII PARP success for Lynparza, putting pressure on Tesaro rival

9 years ago

The clock is ticking on Eli Lilly’s big Alzheimer’s gamble; Pluristem reaches terms on $30M investment from China ...

9 years ago

Portola caps a problem-plagued year with an application for anticoagulant betrixaban

9 years ago

Dipexium shares eviscerated after lead antibiotic flops on a full slate of PhIII endpoints

9 years ago

Novartis promises a speedy CAR-T pitch, boasts about its slate of blockbusters-to-be

9 years ago

Why wait? FDA gives early OK to Merck’s Keytruda for frontline lung cancer

9 years ago

FDA clears Global Blood Therapeutics to focus on key biomarker in pivotal sickle cell trial

9 years ago

Backlash: Harvard experts fret over the fallout from FDA’s OK for Sarepta’s controversial Duchenne drug

9 years ago

China: Fraud not the only reason 1,193 drug applications were withdrawn; Advaxis shares drop

9 years ago

Inovio shares slide after FDA hits it with a hold on lead PhIII HPV program

9 years ago

New Listeria fears spotlighted as Aduro’s CRS-207 is slapped with partial hold

9 years ago

Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal

9 years ago

Zeroing in on Merck rival, GSK steps up to the FDA with its top new vaccine prospect

9 years ago

Merck completes a clinical trial Odyssey, finally bagging an FDA OK for C diff antibody

9 years ago

Let's rethink Clinton's war on pharma; The FDA can't order the genie back into the magic lamp

9 years ago

First page Previous page 1174 1175 117611771178 1179 1180 Next page Last page